Online Control of the Family-wise Error Rate (FWER) for Multi-stage Platform Trials
Listen
Radio episode about this paper
Transcript
Introduction to the show: ident: Statistics. The day in statistics: methods, theory and the inference under them.
Tom: We're looking at the paper: "Online Control of the Family-wise Error Rate (FWER) for Multi-stage Platform Trials".
Jane: Here's the gist of the paper. In platform trials, multiple intervention arms can enter or leave the study at any time, which brings the challenge of how to control the type I error rate In a platform trial, multiple intervention arms can enter or leave the study at any time, which brings the challenge of how to control the type I error rate.
Tom: The ADDIS-Spending (ADaptive DIScarding Alpha-spending) procedure controls the FWER in an online setting Problem Definition and Motivation Platform trials present a challenge regarding error rate control because multiple hypotheses are tested sequentially over time, and the total number of hypotheses is unknown The paper addresses the lack of a method that controls the FWER and allows new arms to be added at any time without prior information While standard two-arm trials focus on a single intervention, platform trials allow multiple treatments to enter at any time point, introducing multiplicity problems since the total number of arms is not known initially.
Jane: The family-wise error rate (FWER) control is usually the standard requirement in a confirmatory clinical trial.
Tom: Proposed Method Development The authors propose the group sequential ADDIS-Spending algorithm to enable interim analyses for each hypothesis in platform trials This method updates the error level of an individual hypothesis at all (interim) analyses whenever new decisions on other hypotheses are made.
Title and authors: Tom: The title itself, "Online Control of the Family-wise Error Rate (FWER) for Multi-stage Platform Trials," tells you right away it's about managing multiple treatments over time without knowing the whole set beforehand.
Jane: And they are led by researchers from Regensburg and Cambridge, who are clearly deep in the statistical weeds of how to handle sequential testing under these complex conditions.
Lu: What’s interesting is that they point out that while other papers have looked at false discovery rate control or multiplicity issues with shared control arms, this paper specifically aims for FWER control while allowing new arms to be added without prior information.
Meng: So, the core problem they are solving isn't just about testing more hypotheses; it’s about maintaining a valid error rate when the structure of the trial itself is changing dynamically.
Lalam: It sounds like they are addressing a gap where previous methods either controlled the false discovery rate or only looked at specific types of shared control, but not this general online environment where arms are added unpredictably.
The paper's summary: Tom: The authors summarize that platform trials naturally create an online multiple testing procedure because the total number of hypotheses is unknown and they are tested sequentially over time.
Jane: They emphasize that family-wise error rate control is the standard requirement for confirmatory clinical trials, so this work is important because it provides a method to achieve that under these dynamic conditions.
Lu: The proposed ADDIS-Spending procedure works by updating the error level of an individual hypothesis at every interim analysis whenever a decision about another hypothesis is made, which prevents that error rate from getting inflated at later stages.
Meng: It seems they are using a specific rule involving a conflict set to decide which hypotheses are being tested and which ones are being discarded or kept for later testing.
Lalam: So, the summary points toward an adaptive approach where the testing level for one hypothesis changes based on what has happened with others in the trial timeline.
The paper's improvements: Tom: The main improvement they suggest is moving away from static alpha spending procedures, which usually have a fixed sequence like a gamma sequence that sums to one, because that just doesn't work well when new arms are entering.
Jane: They introduce the ADDIS-Spending procedure which improves power by using the fraction of non-null hypotheses and specifically exploiting those null hypotheses that turn out to be strictly non-significant.
Lu: The paper claims that this group sequential approach is more powerful than the usual alpha spending because it constrains the alpha cost to specific hypotheses using parameters like lambda and tau, which are different from a simple fixed sequence.
Meng: I'm interested in the claim about power gains when there's a high proportion of non-null hypotheses; that suggests this method is particularly useful when you have many potential treatments to test.
Lalam: And they suggest that there should exist specific values for lambda and tau where the power of this ADDIS-Spending procedure actually beats the performance of a standard alpha spending procedure with the same sequence.
Conclusion: Tom: So, to wrap up, this paper presents the group sequential ADDIS-Spending algorithm as a flexible way to manage multiplicity in online multi-stage platform trials while ensuring FWER control.
Jane: Essentially, it’s an improvement over static methods because it adapts the error level of each hypothesis based on decisions made about other hypotheses at earlier time points.
Lu: The implication is that you can have more efficient interim analyses and better power when you are adding treatments sequentially, even when the total number of arms remains unknown initially.
Meng: From a deployment standpoint, this means you could potentially run longer or test more arms while still keeping the error rate under control without needing perfect upfront planning for every single arm.
Lalam: This whole paper on "Online Control of the Family-wise Error Rate (FWER) for Multi-stage Platform Trials" shows that adaptive methods can provide a more robust way to handle sequential hypothesis testing in these complex trial designs.
Jiangyue Yao, David S. Robertson, Thomas Jaki
Faculty of Informatics and Data Science, University of Regensburg · MRC Biostatistics Unit, University of Cambridge
stat.ME
Submitted: 2026-11-04
Updated: 2026-11-04
License: http://creativecommons.org/licenses/by/4.0/
Importance score: 91/100
The gist: In platform trials, multiple intervention arms can enter or leave the study at any time, which brings the challenge of how to control the type I error rate In a platform trial…
Key concepts
- Platform Trials
- These are clinical trials where multiple intervention arms can enter or leave the study at any point during the trial. This introduces complexity because the total number of possible treatments is unknown initially, making standard error control difficult.
- Family-wise Error Rate (FWER)
- This is a statistical measure that controls the probability of making at least one Type I error (false positive) across all multiple hypotheses tested simultaneously. Controlling FWER ensures that the overall risk of falsely claiming a treatment effect is kept low.
- Group Sequential ADDIS-Spending
- This is an adaptive method where the testing level (alpha) for each hypothesis changes dynamically during interim analyses. It uses a conflict set to manage hypotheses without decisions, ensuring that the error rate remains controlled even as new arms are added or data accumulates.
Terminology
Summary
In platform trials, multiple intervention arms can enter or leave the study at any time, which brings the challenge of how to control the type I error rate In a platform trial, multiple intervention arms can enter or leave the study at any time, which brings the challenge of how to control the type I error rate. p. 0 Online Control of the Family-wise Error Rate (FWER) for
Multi-stage Platform Trials
Jiangyue Yao1
, David S. Robertson2
, and Thomas Jaki1,2
1Faculty of Informatics and Data Science, University of Regensburg, Regensburg,
Germany
2MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
November 5, 2026
Abstract
In platform trials, multiple intervention arms can enter or leave the study at any time, which
brings the challenge of how to control the type I error rate.Where the paper says it
Problem Definition and Motivation
Platform trials present a challenge regarding error rate control because multiple hypotheses are tested sequentially over time, and the total number of hypotheses is unknown The paper addresses the lack of a method that controls the FWER and allows new arms to be added at any time without prior information While standard two-arm trials focus on a single intervention, platform trials allow multiple treatments to enter at any time point, introducing multiplicity problems since the total number of arms is not known initially. The family-wise error rate (FWER) control is usually the standard requirement in a confirmatory clinical trial. p. 1 [9] investigated the possible
multiplicity issues of shared control for platform trials. The family-wise error rate (FWER) control
is usually the standard requirement in a confirmatory clinical trial.Where the paper says it
Proposed Method Development
The authors propose the group sequential ADDIS-Spending algorithm to enable interim analyses for each hypothesis in platform trials This method updates the error level of an individual hypothesis at all (interim) analyses whenever new decisions on other hypotheses are made. The procedure involves defining a conflict set to address the issue where hypotheses without decisions at the current analysis are considered conflicting The proposed group sequential ADDIS-Spending procedure is defined by the rule that the testing level αi,j is predictable under the filtration F−Nt(i,j) and satisfies X i∈S∖C αdi τ − λ ≡ X i∈N αdi τ − λ (Sdi − Cdi) ≤ α for all Hi. p. 5 testing level αi,j is predictable under the filtration F−Nt(i,j)
(defined above) and
X
i∈S\C
αdi
τ − λ
≡
X
i∈N
αdi
τ − λ
(Sdi − Cdi
) ≤ α
for all Hi, 0 ≤ λ < τ ≤ 1 and αi,j < τ . Any sequence of testing level αi,j that satisfies the conditions is referred to as a group sequential
ADDIS-Spending procedure.Where the paper says it
Simulation Results and Performance
Simulation results show that the proposed method achieves valid FWER control and can offer power gains at a comparable sample size The performance of the group sequential ADDIS-Spending procedure depends on trial characteristics, especially the maximum number of comparisons that can be admitted to a platform, the percentage and the effect sizes of non-null hypotheses. The proposed approach has a better performance on power when the proportion of non-null hypotheses is high and the maximum number of allowed hypotheses is large
Comparative Analysis
The simulation study compares GS-ADDIS with classic Bonferroni correction, group sequential Bonferroni correction, and a pre-planned approach proposed by Greenstreet et al. [15] The GS-ADDIS procedure is more powerful than the usual alpha-spending procedure because it constrains the alpha cost to particular hypotheses with parameters λ and τ The stability of power of our procedure with respect to the maximum number of arms is particularly important for a platform trial, where the number of hypotheses is unknown in the beginning. p. 5 Then k(i, j) ≥ r(i) which
implies γk(i,j) ≤ γr(i)
. The group sequential ADDIS-Spending approach is more powerful than the usual alpha-spending
procedure in the sense that it constrains the alpha cost to particular hypotheses with parameters λ
and τ . 2 Proposed group sequential ADDIS-Spending approach
Unlike the usual MAMS design where all hypotheses will be tested at the same calendar time,
there is no fixed order of analysis times in platform trials. Both the sequence of hypotheses and
the sequence of their interim analyses need to be considered in a multi-stage platform trial.Where the paper says it
Where the paper says it
References
[1] Janet Woodcock and Lisa M LaVange. Master protocols to study multiple therapies, multiple diseases, or both. p. 0 1 Introduction
Platform trials, as well as basket and umbrella trials, have recently attracted increasing interest
as innovative and efficient designs due to their efficiency and flexibility. They all fall under the
concept of master protocols, in which multiple questions concerning the same disease or biomarker
are addressed within a unified study [1].Where the paper says it
[2] Sharon-Lise T Normand. The RECOVERY platform. p. 0 Online Control of the Family-wise Error Rate (FWER) for
Multi-stage Platform Trials
Jiangyue Yao1
, David S. Robertson2
, and Thomas Jaki1,2
1Faculty of Informatics and Data Science, University of Regensburg, Regensburg,
Germany
2MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
November 5, 2026
Abstract
In platform trials, multiple intervention arms can enter or leave the study at any time, which
brings the challenge of how to control the type I error rate.Where the paper says it
[3] James Wason, Dominic Magirr, Martin Law, and Thomas Jaki. Some recommendations for multi-arm multi-stage trials. p. 0 In this
paper, we propose an approach to address the multiplicity issue in platform trials. While standard two-arm randomized clinical trials focus on a single intervention, multi-arm-multistage (MAMS) design allows the comparison of multiple treatments with a shared control.Where the paper says it
[4] Dominic Magirr, Thomas Jaki, and John Whitehead. A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection. p. 0 In this
paper, we propose an approach to address the multiplicity issue in platform trials. While standard two-arm randomized clinical trials focus on a single intervention, multi-arm-multistage (MAMS) design allows the comparison of multiple treatments with a shared control.Where the paper says it
[5] Thomas Jaki. Multi-arm clinical trials with treatment selection: what can be gained and at what price? p. 0 In this
paper, we propose an approach to address the multiplicity issue in platform trials. While standard two-arm randomized clinical trials focus on a single intervention, multi-arm-multistage (MAMS) design allows the comparison of multiple treatments with a shared control.Where the paper says it
[6] Nigel Stallard, Susan Todd, Deepak Parashar, Peter K Kimani, and Lindsay A Renfro. On the need to adjust for multiplicity in confirmatory clinical trials with master protocols. p. 0 They all fall under the
concept of master protocols, in which multiple questions concerning the same disease or biomarker
are addressed within a unified study [1]. Platform trials have especially come to the forefront of
clinical research and contributed significantly to the development of treatments for COVID-19 [2].Where the paper says it
[7] Xinping Cui, Emily Ouyang, Yi Liu, Jingjing Schneider, Hong Tian, Bushi Wang, and Jason C Hsu. Statistical principles for platform trials. p. 1 have discussed the benefits and challenges of conducting a platform trial, fewer have focused on the
problem of controlling the overall type I error rate of the trial. [7] introduce some statistical
considerations of error rate metrics for platform trials, where they argue that FDR control does not
comply with current regulatory policy. This design
improves efficiency and flexibility in identifying new treatments, but it also introduces multiplicity
problems, since the total number of arms is not known when the trial starts [6]. While many papers
1
arXiv:2611.Where the paper says it
Where the paper says it
[8] Xiaofei Bai, Qiqi Deng, and Dacheng Liu. Multiplicity issues for platform trials with a shared control arm. p. 1 [8] and Nguyen et al. [9] investigated the possible
multiplicity issues of shared control for platform trials.Where the paper says it
[9] Quynh Nguyen, Katharina Hees, and Benjamin Hofner. Adaptive platform trials: the impact of common controls on type one error and power. p. 0 The ADDIS-Spending (ADaptive
DIScarding Alpha-spending) procedure controls the FWER in an online setting. We propose
the group sequential ADDIS-Spending algorithm to enable interim analyses for each hypothesis
in platform trials.Where the paper says it
[10] David S Robertson, James MS Wason, Franz König, Martin Posch, and Thomas Jaki. Online error rate control for platform trials. p. 0 Online Control of the Family-wise Error Rate (FWER) for
Multi-stage Platform Trials
Jiangyue Yao1
, David S. Robertson2
, and Thomas Jaki1,2
1Faculty of Informatics and Data Science, University of Regensburg, Regensburg,
Germany
2MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
November 5, 2026
Abstract
In platform trials, multiple intervention arms can enter or leave the study at any time, which
brings the challenge of how to control the type I error rate.Where the paper says it
[11] David S Robertson and James Wason. Online control of the false discovery rate in biomedical research. p. 0 Interim analyses in a multistage design offer the opportunity of early stopping for success or futility in clinical trials by
testing the same hypothesis at different time points. Some methods targeting false-discovery
rate (FDR) or family-wise error rate (FWER) control for multi-stage platform trials have been
proposed. This design
improves efficiency and flexibility in identifying new treatments, but it also introduces multiplicity
problems, since the total number of arms is not known when the trial starts [6]. While many papers
1
arXiv:2611.Where the paper says it
Where the paper says it
[12] Sonja Zehetmayer, Martin Posch, and Franz König. Online control of the false discovery rate in group-sequential platform trials. p. 0 Interim analyses in a multistage design offer the opportunity of early stopping for success or futility in clinical trials by
testing the same hypothesis at different time points. Some methods targeting false-discovery
rate (FDR) or family-wise error rate (FWER) control for multi-stage platform trials have been
proposed.Where the paper says it
[13] Adel Javanmard and Andrea Montanari. Online rules for control of false discovery rate and false discovery exceedance. p. 0 Interim analyses in a multistage design offer the opportunity of early stopping for success or futility in clinical trials by
testing the same hypothesis at different time points. Some methods targeting false-discovery
rate (FDR) or family-wise error rate (FWER) control for multi-stage platform trials have been
proposed.Where the paper says it
[14] Jinjin Tian and Aaditya Ramdas. Online control of the familywise error rate. p. 0 Online Control of the Family-wise Error Rate (FWER) for
Multi-stage Platform Trials
Jiangyue Yao1
, David S. Robertson2
, and Thomas Jaki1,2
1Faculty of Informatics and Data Science, University of Regensburg, Regensburg,
Germany
2MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
November 5, 2026
Abstract
In platform trials, multiple intervention arms can enter or leave the study at any time, which
brings the challenge of how to control the type I error rate.Where the paper says it
[15] Peter Greenstreet, Thomas Jaki, Alun Bedding, and Pavel Mozgunov. A preplanned multi-stage platform trial for discovering multiple superior treatments with control of FWER and power. p. 1 [10] and Robertson and Wason [11] discussed how to control the
online error rate for platform trials but without considering multiple stages. It would be worthwhile
to establish a method controlling FWER for a multi-stage platform trial.Where the paper says it
[16] Thomas Burnett, Franz König, and Thomas Jaki. Adding experimental treatment arms to multi-arm multi-stage platform trials in progress. p. 0 Online Control of the Family-wise Error Rate (FWER) for
Multi-stage Platform Trials
Jiangyue Yao1
, David S. Robertson2
, and Thomas Jaki1,2
1Faculty of Informatics and Data Science, University of Regensburg, Regensburg,
Germany
2MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
November 5, 2026
Abstract
In platform trials, multiple intervention arms can enter or leave the study at any time, which
brings the challenge of how to control the type I error rate.Where the paper says it
[17] Tijana Zrnic, Aaditya Ramdas, and Michael I Jordan. Asynchronous online testing of multiple hypotheses. p. 0 Robertson2
, and Thomas Jaki1,2
1Faculty of Informatics and Data Science, University of Regensburg, Regensburg,
Germany
2MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
November 5, 2026
Abstract
In platform trials, multiple intervention arms can enter or leave the study at any time, which
brings the challenge of how to control the type I error rate. Online testing procedures, where
a stream of hypotheses are tested over time and the total number of hypotheses is unknown,
might be a viable choice for error rate control in platform trials.Where the paper says it
[18] John Whitehead. The design and analysis of sequential clinical trials. p. 3 To address this issue, we proposed a group sequential
approach and will introduce it in the next subsection. 2 Proposed group sequential ADDIS-Spending approach
Unlike the usual MAMS design where all hypotheses will be tested at the same calendar time,
there is no fixed order of analysis times in platform trials.Where the paper says it
[19] Vincent Jankovic, Lasse Fischer, and Werner Brannath. Asymptotic online FWER control for dependent test statistics. p. 5 When compared to other alpha-spending procedures, it is claimed that
there must exist τ and λ such that the power of ADDIS-Spending procedure is greater than that of
the alpha-spending procedure (with the same choice of γ sequence) [14]. However, notice that such
an advantage depends on the multivariate distribution of the test statistics. This design
improves efficiency and flexibility in identifying new treatments, but it also introduces multiplicity
problems, since the total number of arms is not known when the trial starts [6]. While many papers
1
arXiv:2611.Where the paper says it
Where the paper says it
Pruning redundant reasoning tokens
The paper introduces the group sequential ADDIS-Spending algorithm to manage multiplicity in online multi-stage platform trials while ensuring FWER control The initial thought for alpha spending involves an infinite non-negative sequence where γi is proportional to a function of the index i, such as γi ∝ i − 1.6 The ADDIS-Spending procedure improves power by utilizing the fraction of non-null hypotheses and exploiting strictly non-significant null hypotheses The group sequential approach is introduced to address issues arising from repeated interim analyses in multi-stage designs where new information becomes available at each stage. p. 2 The ADDIS-Spending procedure is a powerful method for online testing; however, it is not suitable
for platform trials that involve not only multiple arms but also multiple stages. Problems arise
during repeated interim analyses in multi-stage designs, where new information becomes available
at each stage, leading to reallocation of the significance level.Where the paper says it
How the training signal is built
The group sequential ADDIS-Spending procedure requires the testing level αi,j to be predictable under the filtration F−Nt(i,j) and satisfies X i∈S∖C αdi τ − λ ≡ X i∈N αdi τ − λ (Sdi − Cdi) ≤ α for all Hi The suggested significance level is given by the formula αi,j = α(τ − λ)γk(i,j), where k(i, j) indexes the γ value which utilizes all information until time t = t(i, j) The local boundaries for each stage are derived using group sequential design principles based on cumulative estimated treatment effects and current total sample size.
Where the gains come from
Simulation results indicate that the proposed method performs well across a variety of scenarios, though performance naturally depends on trial characteristics The group sequential ADDIS-Spending approach is more powerful than the usual alpha-spending procedure in that it constrains the alpha cost to particular hypotheses with parameters λ and τ It is claimed that there must exist τ and λ such that the power of ADDIS-Spending procedure is greater than that of the alpha-spending procedure (with the same choice of γ sequence). The GS-ADDIS procedure shows particular benefit when the proportion of non-null hypotheses is high The stability of power of our procedure with respect to the maximum number of arms is particularly important for a platform trial, where the number of hypotheses is unknown in the beginning. p. 1 In a platform trial, typically only a few treatments are included in the beginning and additional
arms will be added later. This setting also reflects an online multiple testing procedure, where
hypotheses are tested sequentially over time and the total number of hypotheses remains unknown. However, the
overall power of such an alpha-spending procedure is not convincing since the later hypotheses will
be allocated to a relatively lower testing level. On that basis Tian and Ramdas [14] proposed the
ADDIS-Spending procedure to improve the power performance.Where the paper says it
Where the paper says it
Appendices
A Proof of FWER control provides the proof of Theorem 1 in Section 2.2 by construction of the stagewise-ordered p-values p′di, this is conditionally uniformly distributed under the null, and hence the conditional probability of rejecting hypothesis Hi at decision time di is strictly controlled at testing level αi,j The proof shows that P(V > 0) ≤ E[V] = X i∈H0 E h E 1≤X i∈H0 E [αdi] = X i∈H0 E αdi τ − λ (Sdi − Cdi) The example of updating the alpha level illustrates how the proposed procedure executes when hypotheses are ordered sequentially across stages The tables illustrate all potential boundaries for different hypotheses under various boundary shapes and stopping rules
Simulation Results of FWER control
Tables 12 and 13 outline the FWERs discussed in Section 3.1 when using parameters τ = 1 and λ = 0. p. 1 Let {γi}∞
i=1 be an infinite
non-negative sequence that sums to 1 (P∞
i=1 γi = 1); the alpha level of each hypothesis can be then
written as αi = αγi
. If we assume a maximum number of n hypotheses in online testing, the alpha
level for each hypothesis Hi would be αi =
α
n
for i ≤ n, and αi = 0 for i > n using Bonferroni
correction.Where the paper says it
Green — the paper says it, and the page is printed. Red — no passage carries it, so treat that sentence as unverified. The same check runs on your own text: check a summary against its source, $5.
Improvements for AI systems
-
Adaptive alpha allocation in online testing allows for updating error levels of individual hypotheses whenever new decisions on other hypotheses are made to ensure FWER control in multi-stage platform trials. This enables a more flexible and efficient approach compared to static alpha spending procedures like the usual alpha-spending procedure.
-
The group sequential ADDIS-Spending procedure can be implemented to incorporate interim analyses for each hypothesis by updating alpha allocations across (interim) analyses whenever formal testing decisions are made. This addresses the issue where
alpha level could have already been used up at earlier stages and inflate the error rate.
-
The proposed method allows new arms to be added at any time without prior information by adapting the testing boundaries based on a conflict set of hypotheses that have not yet reached a decision, as described in
A group sequential ADDIS-Spending procedure is defined by the following rule: the testing level alpha i,j is predictable under the filtration F−Nt(i,j)
. -
The system can utilize stage-wise ordering p-values to compute an adjusted significance level alpha i,j for hypothesis Hi at testing time point t(i, j), which is a
group sequential ADDIS-Spending procedure
ensuring thatX i∈S∖C αdi τ − λ ≡ X i∈N αdi τ − λ (Sdi − Cdi) ≤ α for all Hi.
-
The AI system can perform simulations across various platform trial scenarios, including half-overlapping and completely overlapping arms, to evaluate the performance of the GS-ADDIS procedure against classic Bonferroni and pre-planned approaches under conditions where the
independence assumption does not hold.
Abstract
In platform trials, multiple intervention arms can enter or leave the study at any time, which brings the challenge of how to control the type I error rate. Online testing procedures, where a stream of hypotheses are tested over time and the total number of hypotheses is unknown, might be a viable choice for error rate control in platform trials. Interim analyses in a multi-stage design offer the opportunity of early stopping for success or futility in clinical trials by testing the same hypothesis at different time points. Some methods targeting false-discovery rate (FDR) or family-wise error rate (FWER) control for multi-stage platform trials have been proposed. However, a method which controls the FWER and allows new arms to be added at any time without prior information is yet to be established. The ADDIS-Spending (ADaptive DIScarding Alpha-spending) procedure controls the FWER in an online setting. We propose the group sequential ADDIS-Spending algorithm to enable interim analyses for each hypothesis in platform trials. The developed method can update the error level of an individual hypothesis at all (interim) analyses whenever new decisions on other hypotheses are made. We compare alternative approaches with our method in a simulation study. The proposed method yields competitive results in the conducted simulations.
Sources
- Principles of Conditionality and Layering of Error Rates with Application to Platform Trials
- Online control of the false discovery rate in biomedical research
- Asymptotic Online FWER Control for Dependent Test Statistics
Related papers
- Learning Robust Treatment Rules for Censored Data
- Neural Estimation of Summary Statistics for Simulation-Based Inference with Non-Asymptotic Guarantees
- Spectral divide-and-conquer MCMC for long stationary time series
- Improving the Efficiency of Subgroup Analysis in Randomized Controlled Trials with TMLE
- Personalized Federated Vector Autoregression with Personalization Diversity
- Doubly Robust and Efficient Calibration of Prediction Sets for Right-Censored Time-to-Event Outcomes